Sanofi (NASDAQ:SNY) Position Reduced by Captrust Financial Advisors

Captrust Financial Advisors trimmed its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 21.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,027 shares of the company's stock after selling 10,268 shares during the period. Captrust Financial Advisors' holdings in Sanofi were worth $1,834,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SNY. Synergy Asset Management LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. boosted its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new stake in Sanofi during the 4th quarter worth $31,000. Bessemer Group Inc. increased its holdings in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in Sanofi in the fourth quarter valued at about $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $63.33.

Sanofi Stock Performance

SNY stock traded up $0.82 on Friday, reaching $51.68. The company's stock had a trading volume of 2,724,204 shares, compared to its average volume of 2,373,094. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $130.56 billion, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The firm has a fifty day moving average of $53.50 and a two-hundred day moving average of $51.92.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period last year, the company earned $1.78 earnings per share. The company's quarterly revenue was down 11.0% compared to the same quarter last year. As a group, analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.